These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Real-world anti-seizure treatment and adverse events among individuals living with drug-resistant focal epilepsy in the United States. Mao J; Takahashi K; Cheng M; Xu C; Boca A; Song Y; Dandurand A Epilepsia Open; 2024 Aug; 9(4):1311-1320. PubMed ID: 38818833 [TBL] [Abstract][Full Text] [Related]
4. Trends in Antiseizure Medication Initiation, Switch, or Termination in Patients With Newly Diagnosed Epilepsy: A Nationwide Study. Bolin K; Patric B; Tomson T Neurology; 2024 Jul; 103(2):e209500. PubMed ID: 38870473 [TBL] [Abstract][Full Text] [Related]
5. Levetiracetam as a first-line antiseizure medication in WHO grade 2 glioma: Time to seizure freedom and rates of treatment failure. Fairclough S; Goodden J; Chumas P; Mathew R; Maguire M Epilepsia; 2023 Apr; 64(4):857-865. PubMed ID: 36636895 [TBL] [Abstract][Full Text] [Related]
6. The Adverse Effects of Commonly Prescribed Antiseizure Medications in Adults With Newly Diagnosed Focal Epilepsy. Barnard SN; Chen Z; Kanner AM; Holmes MG; Klein P; Abou-Khalil BW; Gidal BE; French J; Perucca P; Neurology; 2024 Oct; 103(7):e209821. PubMed ID: 39270150 [TBL] [Abstract][Full Text] [Related]
7. Effect of drug treatment changes and seizure outcomes on depression and suicidality in adults with drug-resistant focal epilepsy. Mula M; Borghs S; Ferro B; Zaccara G; Dainese F; Ferlazzo E; Romigi A; Gambardella A; Perucca E Epilepsia; 2024 Feb; 65(2):473-482. PubMed ID: 38073337 [TBL] [Abstract][Full Text] [Related]
8. Greater need for treatment optimization in patients with epilepsy initiating adjunctive therapy: Results of a retrospective claims analysis of antiseizure medication drug load in the United States. Connor GS; Labiner DM; Schabert VF; Weingarten M; Wade CT; Stern S; Becker DA Epilepsy Behav; 2024 Mar; 152():109649. PubMed ID: 38277849 [TBL] [Abstract][Full Text] [Related]
9. Adjunctive Brivaracetam in Focal Epilepsy: Real-World Evidence from the BRIVAracetam add-on First Italian netwoRk STudy (BRIVAFIRST). Lattanzi S; Canafoglia L; Canevini MP; Casciato S; Chiesa V; Dainese F; De Maria G; Didato G; Falcicchio G; Fanella M; Ferlazzo E; Fisco G; Gangitano M; Giallonardo AT; Giorgi FS; La Neve A; Mecarelli O; Montalenti E; Piazza F; Pulitano P; Quarato PP; Ranzato F; Rosati E; Tassi L; Di Bonaventura C; CNS Drugs; 2021 Dec; 35(12):1289-1301. PubMed ID: 34476770 [TBL] [Abstract][Full Text] [Related]
10. Adherence to and persistence with lacosamide, perampanel, lamotrigine, and levetiracetam in adult patients with focal epilepsy in Japan: A descriptive cohort study using a claims database. Chen S; Fukasawa T; Ikeda A; Takeuchi M; Shimotake A; Yoshida S; Kawakami K Heliyon; 2023 Apr; 9(4):e15017. PubMed ID: 37064469 [TBL] [Abstract][Full Text] [Related]
11. Spanish consensus on the management of concomitant antiseizure medications when using cenobamate in adults with drug-resistant focal seizures. Carreño M; Gil-Nagel A; Serratosa JM; Toledo M; Rodriguez-Uranga JJ; Villanueva V Epilepsia Open; 2024 Jun; 9(3):1051-1058. PubMed ID: 38573131 [TBL] [Abstract][Full Text] [Related]
12. Antiepileptic Drug Treatment Patterns in Women of Childbearing Age With Epilepsy. Kim H; Faught E; Thurman DJ; Fishman J; Kalilani L JAMA Neurol; 2019 Jul; 76(7):783-790. PubMed ID: 30933252 [TBL] [Abstract][Full Text] [Related]
13. Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs. Marson AG; Burnside G; Appleton R; Smith D; Leach JP; Sills G; Tudur-Smith C; Plumpton CO; Hughes DA; Williamson PR; Baker G; Balabanova S; Taylor C; Brown R; Hindley D; Howell S; Maguire M; Mohanraj R; Smith PE Health Technol Assess; 2021 Dec; 25(75):1-134. PubMed ID: 34931602 [TBL] [Abstract][Full Text] [Related]
14. Response to subsequent antiseizure medications after first antiseizure medication failure in newly diagnosed epilepsy. Hersi H; Saarinen JT; Raitanen J; Peltola J Front Neurol; 2022; 13():1042168. PubMed ID: 36438960 [TBL] [Abstract][Full Text] [Related]
15. Retention Rates and Successful Treatment with Antiseizure Medications in Newly-Diagnosed Epilepsy Patients. Hwang S; An H; Shin DW; Lee HW Yonsei Med J; 2024 Feb; 65(2):89-97. PubMed ID: 38288649 [TBL] [Abstract][Full Text] [Related]
16. Patterns of antiseizure medication utilization in the Human Epilepsy Project. Fox J; Barnard S; Agashe SH; Holmes MG; Gidal B; Klein P; Abou-Khalil BW; French J; Epilepsia; 2023 Dec; 64(12):3196-3204. PubMed ID: 37846772 [TBL] [Abstract][Full Text] [Related]
18. Trends in antiseizure medication prescription patterns among all adults, women, and older adults with epilepsy: A German longitudinal analysis from 2008 to 2020. Hochbaum M; Kienitz R; Rosenow F; Schulz J; Habermehl L; Langenbruch L; Kovac S; Knake S; von Podewils F; von Brauchitsch S; Hamacher M; Strzelczyk A; Willems LM Epilepsy Behav; 2022 May; 130():108666. PubMed ID: 35339390 [TBL] [Abstract][Full Text] [Related]
20. Retention of brivaracetam in adults with drug-resistant epilepsy at a single tertiary care center. Green SF; Hare N; Kassam M; Rugg-Gunn F; Koepp MJ; Sander JW; Rajakulendran S Epilepsy Behav; 2022 Oct; 135():108868. PubMed ID: 35985166 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]